timothy sykes logo
Tempus AI Stock Jumps As ARK, Medtronic, Gilead Fuel Bull Case Thumbnail
ADD US ONG Google News

Tempus AI Stock Jumps As ARK, Medtronic, Gilead Fuel Bull Case

TIM SYKES•UPDATED APR. 15, 2026, 11:33 AM ET
Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

Tempus AI Inc. stocks have been trading up by 10.17 percent amid strong investor optimism on its healthcare AI advancements.

Candlestick Chart

Live Update At 11:32:25 EDT: On Wednesday, April 15, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 10.17%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempus AI (TEM) has been trading like a classic growth story that went out of favor, then started fighting back. From late March to mid‑April, TEM climbed from the low $40s to a recent close near $54.55, a sharp rebound after being down more than 20% year-to-date. That move has been driven by hard news, not hype.

Daily candles show a clear breakout sequence: higher lows from around $42.37 on 2026/03/30 to $45.22 on 2026/03/31, then a series of pushes into the high $40s and, finally, the $50s. Intraday 5‑minute action on the latest session shows steady accumulation, with Tempus AI grinding from roughly $50 at the open toward the mid‑$50s, and tight pullbacks being bought.

Under the hood, TEM is still a heavy‑loss, high‑growth name. Tempus AI generated about $1.27B in revenue, but margins are deeply negative, with an EBIT margin around -17.6% and profit margin near -19%. Cash burn is real, with free cash flow around -$43.1M in the latest quarter, yet the balance sheet carries more than $600M in cash and a current ratio of 3.1, giving Tempus AI runway. For traders, that combination—strong top-line, weak earnings, solid liquidity—often fuels big momentum swings around catalysts.

Why Traders Are Watching Tempus AI Now

Tempus AI is finally giving traders what they want: real clinical validation, big‑league partnerships, and high‑profile sponsorship, all at the same time. The Medtronic trial is the clearest proof point so far. In severe heart valve disease, the joint AI‑based notification platform rolled out across 35 hospitals and drove a 40% jump in surgical interventions and a 27% increase in specialist evaluations. That’s not theoretical. Those are hard, operational numbers, and the market rewarded Tempus AI with a roughly 4.3% pop.

For short‑term traders, that tells you two things. First, TEM headlines tied to concrete outcome data can move the stock fast. Second, the market is starting to see Tempus AI as more than a story stock—it is reacting to execution.

Then there’s the Gilead Sciences news. Tempus AI expanded its multiyear partnership so Gilead gets enterprise‑wide access to the Lens platform and Tempus’ de‑identified multimodal datasets in oncology. That kind of “all‑you‑can‑eat” data and platform access usually means deeper integration into a big pharma workflow, not just a small pilot. Traders reading between the lines see Tempus AI positioning as a core AI infrastructure layer for cancer R&D.

Layer on ARK Invest. Cathie Wood is rotating capital out of mega‑cap tech and semiconductors into Tempus AI, making TEM one of ARK’s largest positions even with the stock still down heavily this year. That type of concentrated bet often becomes self‑reinforcing on both sides—supportive on dips, but punishing if Tempus AI stumbles. Finally, William Blair’s pre‑Q1 diagnostics call, which includes TEM, flags a catalyst calendar. Institutional eyes are turning toward Tempus AI before earnings, and that usually means more volume and wider ranges.

More Breaking News

Conclusion

Tempus AI is acting like a classic momentum education case for traders who study catalysts. The Medtronic trial proves its algorithms can change real‑world clinical behavior, not just generate fancy slide decks. The expanded Gilead agreement shows that top‑tier biopharma is willing to wire Tempus AI’s Lens platform into enterprise‑scale oncology work. ARK’s rotation into TEM adds fuel, putting a loud, visible sponsor behind the precision‑medicine AI theme.

At the same time, Tempus AI is not a widows‑and‑orphans name. TEM is still unprofitable, with negative margins and notable cash burn, even as revenue climbs. That’s exactly the profile that can overshoot both up and down. The recent run from the low $40s to the mid‑$50s shows how quickly sentiment can flip when a stock like Tempus AI strings together a few strong headlines.

For active traders, the roadmap is straightforward: track the news, respect the volatility, and let the price action confirm the story. With the William Blair call and upcoming Q1 numbers on deck, TEM’s catalyst calendar remains packed. As Tim Sykes loves to remind his students, “Patterns repeat, but only if you’re prepared.” That mindset lines up with his broader trading philosophy as well; as millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.”. Tempus AI is giving the market patterns right now—clinical wins, data deals, and big‑money buying. The job for traders is to study those moves, manage risk, and never confuse a hot narrative with a guaranteed outcome.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TEM

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”